Zacks: Brokerages Expect Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) Will Announce Earnings of -$0.14 Per Share

Share on StockTwits

Brokerages expect Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) to announce earnings of ($0.14) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Aerpio Pharmaceuticals’ earnings. Aerpio Pharmaceuticals reported earnings per share of ($0.11) in the same quarter last year, which would indicate a negative year over year growth rate of 27.3%. The business is expected to report its next quarterly earnings results on Thursday, November 5th.

On average, analysts expect that Aerpio Pharmaceuticals will report full year earnings of ($0.15) per share for the current financial year. For the next fiscal year, analysts expect that the business will post earnings of ($0.63) per share. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Aerpio Pharmaceuticals.

Shares of NYSE ARPO traded down $0.03 during midday trading on Friday, hitting $1.56. The stock had a trading volume of 12,059 shares, compared to its average volume of 1,570,297. The company’s 50-day simple moving average is $1.40 and its 200 day simple moving average is $0.92. Aerpio Pharmaceuticals has a fifty-two week low of $0.42 and a fifty-two week high of $1.90.

Aerpio Pharmaceuticals Company Profile

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy.

Further Reading: Ex-Dividend

Get a free copy of the Zacks research report on Aerpio Pharmaceuticals (ARPO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply